Asian Growth Companies Insiders Are Eager To Own

In This Article:

In the midst of global economic uncertainties and trade tensions, Asian markets have shown resilience with modest gains in regions like Japan, while China remains focused on boosting consumption to drive growth. In such a landscape, companies with high insider ownership often signal confidence from those closest to the business, making them intriguing prospects for investors seeking growth opportunities.

Top 10 Growth Companies With High Insider Ownership In Asia

Name

Insider Ownership

Earnings Growth

Zhejiang Jolly PharmaceuticalLTD (SZSE:300181)

23.3%

26%

Seojin SystemLtd (KOSDAQ:A178320)

32.1%

34.3%

Laopu Gold (SEHK:6181)

36.4%

45.7%

Global Tax Free (KOSDAQ:A204620)

20.4%

89.3%

UTour Group (SZSE:002707)

24.1%

32.7%

Oscotec (KOSDAQ:A039200)

21.2%

148.5%

HANA Micron (KOSDAQ:A067310)

18.3%

125.9%

Fulin Precision (SZSE:300432)

13.6%

78.6%

Ascentage Pharma Group International (SEHK:6855)

17.9%

60.9%

Synspective (TSE:290A)

13.2%

37.4%

Click here to see the full list of 644 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.

We'll examine a selection from our screener results.

Akeso

Simply Wall St Growth Rating: ★★★★★★

Overview: Akeso, Inc. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of antibody drugs with a market cap of HK$66.82 billion.

Operations: The company's revenue is primarily derived from the research, development, production, and sale of biopharmaceutical products, totaling CN¥1.87 billion.

Insider Ownership: 19%

Akeso is poised for significant growth with high insider ownership, bolstered by its innovative drug portfolio and strategic clinical developments. Recent approvals for penpulimab and promising Phase III results for ivonescimab highlight Akeso's robust pipeline in oncology. The company trades at 49% below estimated fair value, with revenue expected to grow 28.1% annually, outpacing the Hong Kong market. Despite no recent insider trading activity, Akeso's comprehensive development strategy positions it well in the competitive landscape of cancer immunotherapy.

SEHK:9926 Earnings and Revenue Growth as at Mar 2025
SEHK:9926 Earnings and Revenue Growth as at Mar 2025

BeijingABT NetworksLtd

Simply Wall St Growth Rating: ★★★★☆☆

Overview: BeijingABT Networks Co., Ltd. develops and provides visualized network security technology solutions in China, with a market cap of CN¥5.93 billion.

Operations: The company generates revenue of CN¥743.94 million from its network security segment.